Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Collagen hydrolyzed peptides

Phase 1Small molecule

AAzienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

Collagen hydrolyzed peptides is one of 2 small molecule programs targeting Peptides. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

PeptidesRecruiting

PeptidesPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Peptides

#DrugCompanyPhaseTrials

Imitrex

GGlaxo Dba Glaxosmithkline

Collagen hydrolyzed peptides

AAzienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Peptides1 trial

Plantar Fascitiis: Comparison of ESWT and Collagen Hydrolyzed Peptides

Recruiting·AAzienda Ospedaliero-Universitaria Consorziale Policlinico di Bari·Phase 1·NCT06138236·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Collagen hydrolyzed peptides. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Collagen hydrolyzed peptides compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Collagen hydrolyzed peptides. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAzienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

Related News